However, when several protocols at 1:50 dilution, different by only subtle modifications of the technical conditions (ie, CC1 32 versus 64 min, amplification 4 versus 12 min; see S1 Table) were further tested on a training set of three NSCLC samples, some degree of variability of the staining (ie, faint intensity, incomplete membranous expression) was observed when compared with the gold standard PD-L1 IHC 22C3 pharmDx kit. The gene discussed is CD274; the disease is non-small cell lung carcinoma.